Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Eltrombopag Olamine Patent Expiration

Eltrombopag Olamine is used for increasing platelet counts in patients with chronic immune thrombocytopenia and chronic hepatitis C to facilitate interferon-based therapy. It was first introduced by Novartis Pharmaceuticals Corp in its drug Promacta on Nov 20, 2008. Another drug containing Eltrombopag Olamine is Promacta Kit. 2 different companies have introduced drugs containing Eltrombopag Olamine.


Eltrombopag Olamine Patents

Given below is the list of patents protecting Eltrombopag Olamine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Promacta US8052993

(Pediatric)

 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb 01, 2028 Novartis
Promacta US8052994

(Pediatric)

 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb 01, 2028 Novartis
Promacta US8052995

(Pediatric)

 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb 01, 2028 Novartis
Promacta US8062665

(Pediatric)

 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb 01, 2028 Novartis
Promacta US8071129

(Pediatric)

 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb 01, 2028 Novartis
Promacta US8828430

(Pediatric)

 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Feb 01, 2028 Novartis
Promacta US8052993 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug 01, 2027 Novartis
Promacta US8052994 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug 01, 2027 Novartis
Promacta US8052995 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug 01, 2027 Novartis
Promacta US8062665 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug 01, 2027 Novartis
Promacta US8071129 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug 01, 2027 Novartis
Promacta US8828430 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug 01, 2027 Novartis
Promacta US7547719

(Pediatric)

 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) Jan 13, 2026 Novartis
Promacta Kit US7547719

(Pediatric)

 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) Jan 13, 2026 Novartis
Promacta US7547719 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) Jul 13, 2025 Novartis
Promacta Kit US7547719 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) Jul 13, 2025 Novartis
Promacta US7795293

(Pediatric)

 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Nov 21, 2023

(Expired)

 Novartis
Promacta Kit US7795293

(Pediatric)

 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Nov 21, 2023

(Expired)

 Novartis
Promacta US7795293 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) May 21, 2023

(Expired)

 Novartis
Promacta Kit US7795293 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) May 21, 2023

(Expired)

 Novartis
Promacta US7160870

(Pediatric)

 Thrombopoietin mimetics May 20, 2023

(Expired)

 Novartis
Promacta Kit US7160870

(Pediatric)

 Thrombopoietin mimetics May 20, 2023

(Expired)

 Novartis
Promacta US7160870 Thrombopoietin mimetics Nov 20, 2022

(Expired)

 Novartis
Promacta Kit US7160870 Thrombopoietin mimetics Nov 20, 2022

(Expired)

 Novartis
Promacta US7332481

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta US7452874

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta US7473686

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta US7790704

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta Kit US7332481

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta Kit US7452874

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta Kit US7473686

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta Kit US7790704

(Pediatric)

 Thrombopoietin mimetics Nov 24, 2021

(Expired)

 Novartis
Promacta US7332481 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta US7452874 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta US7473686 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta US7790704 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta Kit US7332481 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta Kit US7452874 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta Kit US7473686 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta Kit US7790704 Thrombopoietin mimetics May 24, 2021

(Expired)

 Novartis
Promacta US6280959

(Pediatric)

 Metal complexes Apr 30, 2019

(Expired)

 Novartis
Promacta Kit US6280959

(Pediatric)

 Metal complexes Apr 30, 2019

(Expired)

 Novartis
Promacta US6280959 Metal complexes Oct 30, 2018

(Expired)

 Novartis
Promacta Kit US6280959 Metal complexes Oct 30, 2018

(Expired)

 Novartis



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eltrombopag Olamine's patents.

Given below is the list recent legal activities going on the following patents of Eltrombopag Olamine.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 24 May, 2023 US8071129
Payment of Maintenance Fee, 12th Year, Large Entity 10 May, 2023 US8062665
Payment of Maintenance Fee, 12th Year, Large Entity 26 Apr, 2023 US8052994
Payment of Maintenance Fee, 12th Year, Large Entity 26 Apr, 2023 US8052995
Payment of Maintenance Fee, 12th Year, Large Entity 26 Apr, 2023 US8052993
Expire Patent
Critical
 10 Oct, 2022 US7790704
Maintenance Fee Reminder Mailed
Critical
 25 Apr, 2022 US7790704
Payment of Maintenance Fee, 12th Year, Large Entity 02 Mar, 2022 US7795293
Payment of Maintenance Fee, 8th Year, Large Entity 23 Feb, 2022 US8828430
Payment of Maintenance Fee, 12th Year, Large Entity 02 Dec, 2020 US7547719


Eltrombopag Olamine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Eltrombopag Olamine Generic API Manufacturers

Several generic applications have been filed for Eltrombopag Olamine.

Given below is the list of companies who have filed for Eltrombopag Olamine generic, along with the locations of their manufacturing plants worldwide.


1. ANNORA PHARMA

Annora Pharma Private Ltd has filed for 2 different strengths of generic version for Eltrombopag Olamine. Given below are the details of the strengths of this generic introduced by Annora Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 12.5MG ACID/PACKET

for suspension Prescription ORAL AB Apr 18, 2024
EQ 25MG ACID/PACKET

for suspension Prescription ORAL AB Apr 18, 2024


Manufacturing Plant Locations
New

Annora Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Annora Pharma as present at those locations.

Country City Firm Name
India
Hyderabad Annora Pharma Private Limited